Cargando…
1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients
BACKGROUND: Invasive aspergillosis (IA) and invasive mucormycosis (IM) are life-threatening invasive fungal diseases (IFDs) that occur in critically ill and/or immunocompromised patients. Approved treatment options have significant limitations in pediatric patients. This study assessed the safety an...
Autores principales: | Arrieta, Antonio C, Segers, Heidi, Deville, Jaime G, Muller, William J, Manzanares, Angela, Neely, Michael N, Bordon, Victoria, Hanisch, Benjamin, Lassaletta, Alvaro, Fisher, Brian T, Autmizguine, Julie, Groll, Andreas H, Sinnar, Shamim, Croos-Dabrera, Rodney, Engelhardt, Marc, Jones, Mark E, Kovanda, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677655/ http://dx.doi.org/10.1093/ofid/ofad500.1532 |
Ejemplares similares
-
2122. Isavuconazonium for Invasive Fungal Therapy: Single-Center Pediatric Experience
por: Mongkolrattanothai, Kanokporn, et al.
Publicado: (2019) -
Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016) -
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018) -
1396. Predictions of Isavuconazonium Sulfate Dosage in Patients Aged 6 Months: <18 Years by Physiologically Based Pharmacokinetic Modeling
por: Desai, Amit, et al.
Publicado: (2018) -
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients
por: Tissot, Frederic, et al.
Publicado: (2017)